Real-world study of a new biologic for moderate to severe plaque psoriasis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study is testing how well a new medication called Xeligekimab works in real-life settings for people with moderate to severe plaque psoriasis. It may help if you are starting this treatment for the first time and want to contribute to learning more about its effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of moderate to severe plaque psoriasis.
- Your doctor has decided that Xeligekimab is a suitable treatment for you, and you have not used it before.
- You are willing to sign a consent form agreeing to participate.
- Your psoriasis is not caused by certain medications (like beta-blockers, calcium channel blockers, or lithium), and you have no allergies to Xeligekimab or its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.
This study tests an investigational drug called SHR-1139 for people with moderate-to-severe plaque psoriasis who have not responded well to previous biologic treatments. The goal is to see if it can reduce psoriasis symptoms safely.
This study tests an oral medication (HSK47388) as a treatment for moderate-to-severe plaque psoriasis, the most common type. It may help reduce symptoms like red, scaly patches and improve quality of life.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.